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Abstract 
 
N-Heterocyclic carbenes (NHCs) are strong donor ligands that form stable complexes with 
many metals, making them popular subjects for research in organometallic chemistry. While 
work with NHCs initially was predominantly in the area of catalysis, applications of NHCs in 
medicinal chemistry have blossomed in recent years. Chemists are investigating NHC 
complexes with increasingly complex NHC components, adding novel functional groups to 
the NHC ring. Among possible functional groups, carbohydrates are naturally abundant and 
well known for their biocompatibility, chirality, water solubility and non-toxicity. It is not 
surprising that carbohydrate groups have been incorporated into NHC ligands to impose 
chirality, increase water solubility, and promote biocompatibility. Such novel NHCs and their 
metal complexes show much promise in catalysis and medicinal chemistry.  
 
In this review, we focus on metal complexes that contain both an NHC ligand and a 
carbohydrate ligand, or have novel NHC ligands bearing pendant carbohydrate groups. We 
discuss synthesis, structural aspects, catalysis and medicinal chemistry. Roles of the NHC 
ligand and carbohydrate moiety related to these properties are highlighted. 
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1. Introduction 
 
The last decade has witnessed dramatic developments in the field of metal complexes of N-
heterocyclic carbenes (NHCs), especially those involving 5-membered NHC ligands. They 
have been investigated as catalysts for olefin metathesis, polymerisation, cyclisation reactions, 
cross-coupling reactions, etc. [1,2]. After the initial burst of research in the catalysis area, use 
of NHC metal complexes in other areas gained attention and is still developing, especially in 
biological and medicinal chemistry. For example, various NHC metal complexes have been 
shown to possess anti-infective activities (e.g., many Ag NHC complexes [3]), anti-biotic 
activities [4] and anti-cancer activities (e.g. some complexes of Ag, Pd, Au, Pt, Ru and other 
metals) [5-7]. 
 
Carbohydrates are naturally abundant, chiral, biocompatible molecules that serve multiple 
functions, e.g., energy storage, cell recognition, adhesion and signalling, etc., in biological 
systems. Thus, carbohydrates have been widely studied across many fields [8-11]. Methods 
for the synthesis of a variety of carbohydrate-functionalised alkyl halides, amines, azides and 
alkynes are well established and many of these compounds are readily available. Herein we 
review metal complexes that incorporate NHC and carbohydrate components. We consider 
two broad classes of complexes—those in which the carbohydrate is a substituent attached to 
an NHC ligand, and those in which the carbohydrate is tethered to the metal more directly.  
 
Imidazolium salts, imidazolinium salts, and triazoles are generally air-stable and easy to work 
with, and their chemistry is well understood. Consequently, modification of the structure of 
their corresponding NHCs is easily achieved by simple synthetic procedures, conveniently 
enabling studies of structure-activity relationships of NHC complexes. So far, in the fields of 
both catalysis and biological chemistry, studies of NHC metal complexes have mostly 
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focused on common NHCs having simple alkyl or aryl substituents on the ring nitrogen(s). 
NHCs incorporating more elaborate substituents (carbohydrates, amino acids, nucleotides, etc) 
offer unique opportunities, especially in biological fields. These more elaborate NHCs are 
being increasingly studied, but much work remains to be done. The purpose of this review is 
to summarize work to date concerning NHC complexes in which the NHC ligand carries a 
carbohydrate-based substituent. 
 
Many research groups have begun to put effort into studying these new types of NHCs, to 
understand their properties and to determine what they can provide to modern chemistry. To 
date, the carbohydrate groups investigated have typically been monosaccharides based on D-
glucopyranose, attached via the anomeric carbon (C1), C2, or C6 (Fig. 1). Metal complexes 
that contain both a simple NHC ligand and a separate carbohydrate ligand are also included 
in our discussion.  
 
 
Fig. 1. Common modes of attachment of D-glucopyranose moieties to an NHC. 
 
2. Synthesis 
 
While a great variety of NHC complexes are known, including examples based on N,N-
heterocycles, N,S-heterocycles, "normal" and "abnormal" NHCs, to date NHC-carbohydrate 
complexes appear only to have been reported for the 5-membered nitrogen-containing NHCs 
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imidazolidinylidene, imidazolylidene and 1,2,3-triazolylidene (Scheme 1). These NHCs are 
easily derived from their precursor imidazolinium salts, imidazolium salts and 1,2,3-triazoles 
respectively, by deprotonation (at C2 of imidazolinium or imidazolium ions and at C5 of 
1,2,3-triazoles) using an organic or inorganic base. Common synthetic pathways [1] to these 
precursors are summarized in Scheme 1. 
 
 
Scheme 1. 
 
When NHCs are synthesized from a pre-formed heterocycle, the substituents on N are 
typically limited to primary and secondary alkyl groups (including benzylic and allylic 
groups) [12,13]. If aryl or t-butyl substituents on N are required, the NHC can be constructed 
from the parent amine(s) via appropriate ring formation pathways [14-16]. For NHCs bearing 
aryl substituents on N, the NHC can also be obtained via routes involving N-arylation of a 
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pre-formed heterocycle, for example reactions catalysed by Cu or Pd  [17-19]. The Cu(I)-
catalyzed Huisgen 1,3-dipolar cycloaddition (“click”) reaction provides easy access to a great 
variety of triazoles [20,21].  
 
From Scheme 1, it is apparent that carbohydrates functionalised with halide or amino groups 
(highlighted in dashed boxes) are potential building blocks for NHCs that have pendant 
carbohydrate groups. For a comprehensive monograph of carbohydrate synthesis see Stick 
and Williams [22]. 
 
Methods for synthesis of NHC-metal complexes have been reviewed  [23,24]. Briefly, the 
most common methods for synthesizing NHC-metal complexes fall into the following three 
classes. 
 
1.  The free carbene method  [25]. In this method, the azolium salt is deprotonated by 
a strong base, and the resulting NHC is then allowed to react with a metal source 
to form the metal-NHC complex. This method is limited to azolium salts that do 
not contain base-sensitive functional groups and requires rigorously dry and 
oxygen-free conditions, and so is not widely used. 
 
2.  The in situ deprotonation method. Here, the azolium salt is allowed to react with a 
mild base in the presence of a metal source. During this procedure the NHC is 
generated in situ and quickly binds to the metal centre, forming the target complex. 
This method can be more tolerant of functionality than the free carbene method 
and does not require rigorously dry conditions. The base can either be derived 
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from the metal source (e.g., acetate from Pd(OAc)2 [26], O2- from HgO [27]) or it 
can be added separately. 
 
3.  The Ag-NHC transfer method [28]. Here, a labile Ag-NHC complex is prepared 
first, and then used to transfer the NHC ligand to a second metal. Metals that can 
be used as sources of NHCs in NHC-transfer reactions include Hg and W, but Ag 
is by far the most commonly used. Ag-NHC complexes are easily prepared from 
azolium salts and Ag2O, and when used in NHC-transfer reactions with halide 
complexes of other metals, a driving force is precipitation of the silver halide. The 
Ag-NHC transfer method is simple, fast, proceeds under very mild conditions, and 
is tolerant of a wide range of functionality in the azolium salt/NHC, and the final 
product is often easy to separate and purify, thus is very popular amongst NHC 
chemists. 
 
Applications of these methods to the synthesis of carbohydrate-containing NHC-metal 
complexes are outlined in subsequent sections in this review.  
 
3. Carbohydrate N-heterocyclic carbene complexes in catalysis 
 
N-Heterocyclic carbenes have attracted interest as nucleophilic catalysts in, for example, 
polymerizations [29], but the main interest of NHCs in catalysis focuses on their use as 
ligands in catalytic metal complexes [30]. As ligands, NHCs have similar properties to 
phosphines, such as the ability to stabilise metals in various oxidation states [31], but NHC 
complexes have some significant advantages over phosphine complexes. For example, NHCs 
tend to bind metals more strongly than phosphines, and resist dissociation from the metal 
centre, so NHC-metal complexes tend to be more robust than analogous phosphine 
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complexes [31,32]. Moreover, whereas phosphines are typically air-sensitive and can be 
difficult to synthesize and purify, especially when functionalized, NHCs are readily 
accessible via azolium salts, which are usually crystalline. Consequently, compared with 
phosphine complexes, NHC complexes offer greater opportunities for exploration of 
structure-activity relationships. Examples of reactions that have been catalyzed by NHC 
metal complexes include, but are not limited to, ruthenium-catalyzed olefin metathesis, 
platinum-catalyzed olefin hydrosilylation, palladium catalyzed Mizoroki-Heck reactions, 
Suzuki-Miyaura reactions and umpolung reactions [33]. 
 
With these advantages in mind, chemists sought to exploit additional functionality in NHCs 
as catalysts. In early attempts to employ NHC metal complexes in asymmetric catalysis, 
chiral functional groups were incorporated as N-substituents or into the backbone of NHCs. 
The challenge in this area is the choice of a cheap yet effective chiral scaffold to attach to the 
NHC [34]. Certain carbohydrates have potential as suitable chiral scaffolds as they are cheap, 
offer structural diversity, and are readily available compounds with well-defined chirality. 
Studies of NHCs containing carbohydrates in order to incorporate a chiral motif into the 
ligand have already emerged in the field of catalysis [35]. 
 
3.1 Carbohydrate NHC metal complexes in stereoselective catalysis 
 
In 2007, Nishioka and coworkers synthesized an imidazolium salt 1 (Scheme 2) having an 
acetylated β-D-glucopyranose moiety as an N-substituent, via an SN2 reaction of α-D-
glucopyranosyl bromide with 1-methylimidazole. Salt 1 was converted into an Ag-NHC 
complex 2 and a subsequent transmetallation reaction gave the 1,2,3,4,5-
pentamethylcyclopentadienyl (Cp*) NHC-iridium complex 3 (Scheme 2) [36]. An ESI-MS 
study of 3 [36] in methanol solution found no evidence for cleavage of the bond linking the 
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carbohydrate moiety and the NHC nitrogen atom, suggesting that the carbohydrate-NHC has 
similar stability to other NHCs [36]. X-ray diffraction studies showed that the Ir-NHC 
binding in 3 was similar to that seen in the closely-related complexes 4 [37] and 5 [38], 
which are catalysts for C-H activation and Oppenauer oxidation of alcohol. In the solid state, 
3 adopts a conformation in which the Cp*IrCl2 moiety is oriented towards the α-face of the 
carbohydrate moiety, and NOESY NMR studies showed that this conformation is retained in 
solution [36]. The observation that the conformation seen in the solid state persists in solution 
suggests that the steric asymmetry in the carbohydrate moiety might influence the 
stereochemical course of reactions at the metal centre. Complex 3 promoted H-D exchange 
reactions [36], but its use for asymmetric catalysis has not been reported.  
 
Scheme 2. 
 
Also in 2007, Glorius and coworkers synthesized the imidazolium salt 6 bearing a pivalate-
protected D-galactopyranose as one of the N-substituents (Scheme 3), as well as imidazolium 
salts 7 and 8, bearing acetate-protected and unprotected D-glucopyranosyl substituents, 
respectively (Scheme 3). When AgNO3 was used instead of AgOTf to promote the 
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displacement of bromide from the α-D-glucopyranosyl bromide starting material, the 
imidazolium salt 7 was obtained as a 3:7 mixture of α and β anomers [39]. Compound 7 
served as a precursor to carbohydrate-bearing Ag- and Pd-NHC complexes 9 and 10 (Scheme 
3); attempts to synthesize 10 directly from 7 and a palladium source were unsuccessful [39]. 
 
 
 
Scheme 3. 
 
While both groups demonstrated that carbohydrate-functionalized NHC complexes could be 
synthesized and were robust enough to serve as catalysts [36,39], their use as catalysts in 
stereoselective synthesis has not yet been reported. However, Glorius and coworkers [40-42] 
explored the use of 1,3-bis(2,4,6-trimethylphenyl)imidazol-2-ylidene (IMes) and various 
carbohydrate-NHCs as catalysts for "conjugated umpolung" annulation [43-45] reactions 
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(Scheme 4). The carbohydrate-NHCs 6-8 (structures shown in Scheme 3) were generated in 
situ by treatment of the corresponding imidazolium salts with base, but could not be isolated. 
While the NHCs served as catalysts and promoted conjugated umpolung annulation in good 
yield, the stereoselectivities of the reactions were modest. 
 
 
Scheme 4. 
 
Keitz and Grubbs synthesized Ru complexes 11 and 12 from similar imidazolium-based 
precursors to those used by Glorius and coworkers [46]. These complexes (Scheme 5) were 
evaluated as catalysts for ring-opening metathesis polymerization, ring-closing metathesis, 
cross-metathesis, and asymmetric ring-opening cross-metathesis reactions at 40 °C. The 
results (examples are included in Scheme 6) were compared with those obtained for "non-
carbohydrate" ruthenium-based catalysts 13-15 at 30 °C. 
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Scheme 5. 
 
The catalytic activities of 11-15 were evaluated for ring-opening metathesis polymerization 
(ROMP) of cyclooctadiene (Scheme 6). At 100:1 monomer to catalyst ratio, 11 and 12 
showed similar  activity, and although initiation was slow, both catalysts promoted >95% 
conversion within 2 h at 30 °C. This activity was lower than that of 14 but similar to that of 
second generation Grubbs catalyst 15 and far superior to that of first generation Grubbs 
catalyst 13.  
 
Curiously, for ring-closing metathesis (RCM), initiation of catalysis of was more rapid and 
the conversion attained was higher using the D-galactose-derived complex 12 compared with 
the D-glucose-derived catalyst 11. The activities of the carbohydrate-based catalysts 11 and 
12 were on a par with those of the non-carbohydrate catalysts 13-15. The conversions 
attained in a cross-metathesis reaction were also similar using either the carbohydrate-based 
catalysts 11 and 12 or the non-carbohydrate catalysts 13-15. Interestingly, cross-metathesis 
reactions conducted using the carbohydrate-based catalysts had poorer E/Z stereoselectivity, 
whereas the non-carbohydrate catalysts 13-15 afforded a significant preference for the 
product of E stereochemistry. Complexes 11 and 12 were evaluated in a number of 
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asymmetric ring-opening cross-metathesis reactions, but again showed poor E/Z 
stereoselectivity and poor to modest enantioselectivity.  
 
 
 
Scheme 6. 
 
More recently, in 2014, Bower and Galan reported a synthetic route from 2-amino-2-
deoxysugars to imidazolium and imidazolinium salts with monosaccharide units as N-
substituents (Scheme 7). In contrast to earlier studies in which the carbohydrate units were 
connected to the imidazol(in)ium ring at the anomeric position, in this study carbohydrates 
were attached to the ring via the C2 position. The nitrogen atoms on the 2-amino-2-deoxy-
sugars were incorporated into the imidazol(in)ium ring [47]. The imidazol(in)ium salts were 
converted into Rh-NHC complexes 16a-e and 17a-c (Scheme 7) that were catalysts for 
reduction of ketones by diphenylsilane (Scheme 8). 
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Scheme 7. 
 
 
 
 
Scheme 8. 
 
  
 16
These catalysts promoted reduction of unsymmetrical ketones in yields up to ca. 96% and 
with ee's up to 62%. There was no significant difference between results obtained using 
complexes incorporating saturated (17) or unsaturated (16) NHCs. It is notable that catalysts 
containing the simplest NHCs (those derived from methyl 2-amino-2-deoxy-3,4,6-tri-O-
methyl-β-D-glucopyranose) gave the best results, with bulkier alkoxy groups leading to lower 
yields and lower enantioselectivity. Amongst the series of catalysts 17a-c, the catalyst in 
which the carbohydrate group is connected via an equatorial bond to the NHC unit (17a), 
showed superior activity (both in terms of enantioselectivity and yield obtained). This result 
is promising, showing that the carbohydrate NHC is able to induce chirality at the active site 
of the Rh complex. However, the achievement of only modest enantioselectivity, and the fact 
that larger substituents on the chiral (carbohydrate) component actually led to reduced 
enantioselectivity suggests that the asymmetry associated with the carbohydrate group may 
be too far from the catalytic metal centre to impart strong chiral induction. 
 
In summary, some synthetic pathways to metal complexes of NHC ligands incorporating 
carbohydrate units have been established. Synthesis, characterization, and (in some cases) 
catalytic activity of these complexes have been compared with their non-carbohydrate 
analogues. The catalytic studies so far are based on a limited range of reactions and 
uncomplicated substrates. The overall catalytic activities of complexes containing 
carbohydrate-NHC ligands are comparable to those reported for non-carbohydrate catalysts, 
but in experiments to achieve chiral induction, the enantioselectivity achieved was not 
impressive. These frustrating results perhaps discouraged further studies of the use of 
carbohydrate-NHC complexes in catalytic reactions involving more complicated substrates. 
The low enantioselectivity might be due to the carbohydrate motif being too far away from 
the active site of the catalyst (metal centre). This problem might be ameliorated by 
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incorporating carbohydrate groups into chelating ligands that can more efficiently impose 
chirality on the catalytic centre. For example, it might be beneficial to investigate complexes 
incorporating more complicated carbohydrate structures (e.g., oligosaccharides), or 
carbohydrate derivatives with different degrees of conformational flexibility, despite the 
increased synthetic complexity. 
 
3.2  Carbohydrate NHC complexes as water soluble catalysts 
 
Incorporation of carbohydrate groups into NHC ligands is an efficient way of increasing 
hydrophilicity, potentially leading to water-soluble catalysts. Towards this aim, several 
studies have been conducted to use NHC carbohydrate complexes as catalysts of reactions in 
water [35]. 
 
Lin and coworkers have reported the synthesis of a series of Ag and Pd complexes 
incorporating D-glucopyranoside-NHC ligands (Scheme 9). The carbohydrate moieties were 
connected to the N atoms of the NHC via the C6 position [48]. An interesting feature of the 
synthesis was the demonstration that after the metal-NHC complexes were formed, it was 
possible to deprotect the carbohydrate moieties (i.e., cleave the benzoate esters) under 
strongly basic conditions by treatment with NaOMe, without disruption of the NHC-Pd 
bonding. 
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Scheme 9. 
 
 
Scheme 10. 
 
Compared with Pd(OAc)2, compounds 21a-c showed better catalytic activity toward the 
Suzuki-Miyaura coupling reaction in water (Scheme 10), especially the coupling of o-
bromobenzoic acid with phenylboronic acid at 0.05 mol% catalyst loading, for which yields 
of 88%-95% were obtained. Interestingly, the catalytic efficiency increases with the length of 
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the alkyl substituent on the imidazolylidene ligand. Compound 21a, possessing a methyl 
substituent on the imidazolylidene ligand, was not stable and showed consistently lower 
catalytic activity than 21b and 21c.  
 
Li and coworkers reported the results of catalyst recycling in the Suzuki-Miyaura cross-
coupling reaction catalyzed by Pd(OAc)2/DABCO/PEG-400 [49]. They found that 21a and 
21b could be recycled in the same way. Although catalytic activity started to decline when 
the catalyst was used for the third time due to decomposition, catalyst stability was enhanced 
by the presence of tetrabutylammonium bromide (TBAB), in which case no significant loss 
of activity was noted when catalysts were reused up to three times [48]. An interesting aspect 
of this study is the demonstration of the coexistence of two different conformations of the 
palladium complexes 20 in solution as revealed by two sets of 1H NMR signals (see Section 
5).  
 
In 2014 Nishioka and coworkers synthesized an interesting imidazolium salt 22 (Scheme 11) 
that was composed of two NHCs and a triazole moiety incorporating a tetraacetyl-D-
glucopyranosyl moiety as a carbohydrate substituent. This ligand was synthesized using 
"click" chemistry, and served as a precursor of Pd complex 23 [50]. 
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Scheme 11. 
 
 
Scheme 12. 
 
Compound 23 served as a catalyst for a Suzuki-Miyaura cross-coupling reaction between 
phenylboronic acid and 4'-bromo- or 4'-chloroacetophenone in water (Scheme 12). Under the 
reaction conditions employed, the presence of K2CO3 resulted in deprotection of the 
glucopyranosyl substituent (i.e., base-catalysed hydrolysis of the acetate groups), which then 
enhanced the water solubility of the catalytic species. In the reaction between 4'-
bromoacetophenone and phenylboronic acid, the catalyst promoted formation of the coupling 
product (4-phenylacetophenone) in 98% at a catalyst loading of 10-2 mol%, and 76% at a 
catalyst loading of 10-3 mol%. The catalyst was less effective in promoting Suzuki-Miyaura 
cross-coupling of 4'-chloroacetophenone and phenylboronic acid, with catalyst loadings of 
0.5 mol% being required to achieve yields of 56% after extended time periods.  
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While these studies by the groups of Lin and Nishioka demonstrated the potential of 
carbohydrate-NHC complexes as catalysts for reactions in water, the spectrum of catalytic 
activity has scarcely been explored. It will be beneficial to test these and related complexes in 
more complicated catalytic systems involving more highly functionalised substrates in future 
studies, and benchmark activities against those of existing catalysts not incorporating 
carbohydrates [33].  
 
4. Carbohydrate NHC complexes in medicinal chemistry. 
 
Mostly studied for their catalytic activity, NHC metal complexes have also exhibited 
biological activities, both in vitro and in vivo. Complexes of form [Au(NHC)2]+ have been 
reported to exhibit anti-cancer activities and were shown to cause mitochondrial membrane 
permeabilisation and induce apoptosis in cancer cells [51,52]. The anti-fungal and anti-
bacterial activity of (NHC)AuCl complexes have been reported by Günal et al. [53], and their 
compounds had minimum inhibitory concentration (MIC) values lower than 12.5 µg/mL 
towards S. aureus and E. facecalis bacteria and the fungi C. albicans and C. tropicalis. 
Biological activity (anti-cancer, anti-bacterial, anti-fungal, etc) has also been reported for 
NHC complexes of other metals, e.g., Ni [54], Ru [55,56], Ag [57,58], Cu [59], Pd [60,61]. 
 
Unlike NHCs, carbohydrates originally attracted the attention of organometallic chemists due 
to their roles in a variety of biological signalling and recognition processes. Their widespread 
biological importance made carbohydrates interesting starting materials for the synthesis of 
biologically active metal complexes. For the purposes of discovering novel classes of metal 
drugs, many carbohydrate ligands have been designed, synthesized and attached to different 
metal centres. There are many reviews [8-11] on this topic, including a detailed book chapter 
covering the research up to 2013 [62]. Despite a number of studies of NHC-metal complexes 
  
 22
and carbohydrate-metal complexes in the bio-related research fields mentioned above, the 
medicinal properties of metal complexes containing both NHC ligands and carbohydrates are 
rarely discussed. Here we review studies of such compounds. 
  
4.1 N-Heterocyclic carbene analogues of Auranofin 
 
Auranofin (Fig. 2) is a well-known anti-arthritic Au(I) drug containing a carbohydrate ligand. 
It has been marketed under the brand name Ridaura® for three decades [63]. Auranofin has 
been known to show anti-cancer activity [64] and it is currently the subject of at least three 
clinical trials concerning a range of cancers [65-67]. Auranofin has attracted a great deal of 
interest because it displays a number of interesting biological activities including activity 
against some difficult to treat cancers, such as osteosarcoma  [68,69]. 
 
To date, the anti-cancer activity of Au-based drugs is largely believed to be due to the ability 
of Au to bind to the selenocysteine residue at the active site of thioredoxin reductase (TrxR). 
TrxR, found in both mitochondria and in the cytosol, is a key player in processes that protect 
cells from effects of oxidative damage. The biological pathway involving TrxR is 
summarised in Fig. 2 [70,71]. 
 
 
Fig. 2. Structure and proposed mode of action of Auranofin. 
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Critical to the functioning of TrxR are cysteine and selenocysteine residues at the active site. 
In the reduced state, these residues exist in the thiol (–SH) and selenolate (–Se-) forms, and 
when TrxR reduces its target protein (thioredoxin, Trx), these residues form a S–Se bond 
(analogous to the disulfide bond). Thioredoxin goes on to reduce disulfide bonds in other 
proteins that were formed by reactions with oxidative species in cells. After binding to 
Auranofin, TrxR loses its ability to repair proteins that have suffered oxidative damage, thus 
making cells susceptible to oxidative damage, and eventually the cells undergo apoptosis 
(controlled cell death) [70]. 
  
The carbohydrate thiolate ligand of Auranofin is labile and can be displaced by other 
biological thiols (cysteine, albumin, etc.) [72-74]. It has been proposed that such exchange 
reactions with serum albumin are important in distributing Au via the bloodstream [73]. 
 
Baker and coworkers were the first to prepare Auranofin analogues 24a-e (Scheme 13), 
which retained the tetraacetylthioglucopyranose moiety but incorporated an NHC ligand in 
place of the PEt3 group [75]. The purpose of this study was to obtain complexes that might 
mimic Auranofin due to the similarity between NHCs and phosphines as metal-binding 
ligands, while exploiting the relative ease of synthesis of imidazolium salts to access 
complexes of a range of NHC ligands having different steric and lipophilic characteristics. 
Interestingly, whereas cationic [Au(NHC)2]+ complexes are believed to have anti-
mitochondrial activity and cause swelling of isolated mitochondria [76], preliminary 
investigations of NHC analogues of Auranofin did not reveal any mitochondrial-swelling 
behaviour for these neutral complexes [77]. 
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Scheme 13. 
 
 
Scheme 14. 
 
In 2011, Nolan and coworkers screened a wide variety of Au(I) complexes, including neutral 
Au(I) complexes {(NHC)AuX (X = halide or a carboxylate-bound amino acid)} and cationic 
Au(I) complexes {[Au(NHC)2]+, [Au(NHC)(PR3)]+} against human breast cancer cell line 
MDA MB231 and human prostate cancer cell line LNCaP [78]. Amongst the complexes 
tested, the NHC Auranofin analogue 25 and the cationic Au(I) complex 26 (Scheme 14), 
which both incorporated the same sterically-encumbered NHC ligand, showed potential anti-
cancer activities (IC50 < 10µM). The authors also reported that generally cationic Au(I) 
complexes (IC50 < 1µM) were more effective than neutral analogues bearing the same NHC 
ligand (2µM < IC50 <10µM) against both cell lines. It was suggested that this phenomenon 
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was perhaps because lipophilic cations are more likely to accumulate in mitochondria, thus 
affecting the overall activity of the drug. 
 
 
Scheme 15. 
 
Later, Tacke and coworkers tested Auranofin analogues 27-29 (Scheme 15) and their 
(Cl,Br)Au(NHC) precursors against Caki-1 (renal) and MCF7 (breast) cancer cells in 
vitro [79]. Compounds 27 and 28 exhibited low IC50 values (48 h) against both cell lines, 
while 29 was active against the MCF7 cell line but not the Caki-1 cell line. This study 
concluded that, generally, (Ac4GlcS)Au(NHC) complexes are more effective than their 
(Cl,Br)Au(NHC) precursors. While partitioning coefficients were not reported, the four 
aromatic substituents on the NHC ligand would clearly cause complexes 27-29 and their 
(Cl,Br)Au(NHC) precursors to be highly lipophilic and poorly soluble in biological media. It 
was suggested that the carbohydrate moiety in 27-29 might have increased the solubility of 
these complexes, thereby accounting for their improved activity compared with the 
(Cl,Br)Au(NHC) complexes. 
 
Recently, Casini’s group synthesized a new Auranofin analogue (32a and 32b, Scheme 16) 
containing an NHC ligand incorporating a coumarin derivative as a fluorescent 
appendage [80]. These fluorescent NHC complexes, along with their precursor imidazolium 
salt (30) and (NHC)AuCl complex (31) and cisplatin, were tested against the human cancer 
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cell lines A2780 (ovarian), MCF-7 (breast), and A549 (lung), with (non-cancerous) human 
embryonic kidney HEK-293T cells as a control. The precursors 30 and 31 showed much 
lower activity compared with cisplatin, while the glucosethiolate complex 32b showed only 
weak activity, and only against MCF-7 cells. The tetraacetylglucosethiolate complex 32a, 
however, exhibited cytotoxicity against both A2780 and MCF-7 cells and was similar in 
efficacy to cisplatin against MCF-7 cells.  
 
 
 
Scheme 16. 
 
The selectivity of these complexes to affect cancer cells rather than the non-cancerous HEK-
293T cells was poor, although, interestingly, the imidazolium salt 30 appeared to be more 
toxic to the cancer cell lines than to the HEK-293T cells. Due to the lack of activity of the 
glucosethiolate complex 32b, the authors concluded that the presence of the glucopyranosyl 
moiety did not enhance the uptake of the compound via the GLUT-1 transporter.  
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In studies [80] using isolated and purified enzymes, complexes 32a and 32b were shown to 
inhibit both cytosolic and mitochondrial thioredoxin reductase (TrxR), the latter more 
strongly, but were less effective inhibitors than Auranofin. However, 32a and 32b, as well as 
Auranofin, showed little or no inhibition of glutathione reductase and glutathione peroxidase. 
Interestingly, the inhibitory profile demonstrated by 32a and 32b against isolated TrxR and 
GR is similar to that seen previously for cationic [Au(NHC)2]+ complexes [51,52]. When 
A2780 cells were incubated with 32a, fluorescence microscopy studies [80] showed that the 
fluorescent tag was taken up by cells and was accumulated in the nuclei. Unfortunately, the 
limited fluorescence of the complex required concentrations of 20 µM for efficient 
visualization, and at these concentrations the complex may have rapidly led to cell death. 
More detailed studies are needed to determine whether the complex 32a remains intact 
throughout the experiment, or whether the NHC-coumarin unit and/or the 
glucopyranosylthiolate moiety become displaced from gold by other ligands in the biological 
milieu. 
 
In 2015, Casini's group published a new study of series of homobimetallic complexes 33-35 
that each contain two Au(I) centres linked by an NHC-phosphine, but which contain 0, 1, or 2 
carbohydrate moieties (Scheme 17) [81]. These complexes showed inhibition of isolated 
TrxR and showed some anticancer activity in vitro (Scheme 17). It is notable that addition of 
the sugar component did not increase anti-cancer activity; for the lung cancer cell line A549, 
the addition of the carbohydrate moieties actually decreased the cytotoxicity. 
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Scheme 17 
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The same group also synthesized Au(I) complexes 36 and 37, which served as precursors of 
several heterobimetallic complexes, including 38. Heterometallic Au(I)-Ru(II) complex 38 
showed activity only against the A2780 ovarian cancer cell line. Based on these data, it is 
difficult to draw conclusions about the role and significance of the carbohydrate moiety in the 
biological activity of these compounds. 
 
4.2 Incorporating a Carbohydrate onto Imidazolidene Ligands in Metal Complexes 
 
In 2010, Skander et al. reported the synthesis of a series of NHC platinum complexes 
containing mutually trans amine and NHC ligands bound to a PtI2 core [82]. Amongst this 
series was 39 (Scheme 18), which incorporated a tetraacetylglucopyranosyl substituent on the 
NHC ligand. Complex 39 was synthesized via a transmetallation route involving an Ag-NHC 
complex as an intermediate, generated in situ. Many of the trans-(NHC)(amine)PtI2 
complexes exhibited reasonable cytotoxic activity against both cisplatin-sensitive and 
cisplatin-resistant cell lines. It was suggested the activity against cisplatin-resistant cell lines 
might be due to the trans geometry the complexes, which would result in formation of Pt-
DNA adducts different to those resulting from cisplatin, and which would be less susceptible 
to the DNA repair mechanisms present in cells that had already acquired resistance to 
cisplatin [83]. Sadly, no biological studies of 39 were reported, so whether or not the 
presence of the carbohydrate moiety affects the cytotoxicity of trans-(NHC)(amine)PtI2 
complexes is unknown. 
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Scheme 18. 
 
5. Structural complexity in carbohydrate NHC transition metal complexes 
 
As mentioned earlier, Lin’s group found that the NMR spectra of solutions containing Pd 
complexes 20a-c (Scheme 8) each showed two distinct sets of signals, a result that was 
attributed to the existence of two distinct conformational isomers in solution [48]. The 
authors considered the possibility of isomers in which the two NHC groups are mutually cis 
or trans about the Pd centre, but this possibility would seem unlikely given that the 13C NMR 
signals due to the Pd-C carbons in each form had very similar chemical shifts. Instead, the 
authors concluded [48] that the distinct NMR spectra corresponded to trans-syn and trans-
anti isomers (conformations) (Fig. 3). Evidently, steric interactions between the NHCs 
(carrying a bulky carbohydrate substituent) and the two bromido ligands attached to the Pd 
centre are substantial, so that rotation of the NHC units about the Pd-C axis is sufficiently 
slow that the two conformations do not interconvert on the NMR timescale.  
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Fig. 3. Isomerism in Pd-NHC complexes 20a-c 
 
Interestingly, Lin and coworkers were able to isolate trans-syn 20a (R = Me) and trans-anti 
20b (R = Et) and characterised both by X-ray diffraction studies. In the crystal structures of 
20a and 20b, the NHC planes are (very) roughly parallel to one another, and (very) roughly 
orthogonal to the Pd coordination plane. This structural motif is characteristic of many trans-
M(X)2(NHC)2 systems. Glorius and coworkers reported a similar motif for trans-
PdCl2(NHC)2 complex 10. The crystal structure determined for 10 contained two 
independent Pd complexes, but both were trans-anti forms [40-42]. 
 
For solutions containing 10, in contrast to the situation for 20a-c, only a single set of signals 
was seen in the 1H and 13C NMR spectra [40-42]. It may be that in 10, the PdCl2 core is 
sufficiently small to permit rotation of the NHC ligands about the Pd-C axis that is rapid on 
the NMR timescale, so that trans-syn and trans-anti forms interconvert rapidly and present a 
single set of averaged signals in the NMR spectra. An alternative possibility [48] is that the 
NHC groups inherently provide sufficient steric bulk around the metal centre in 10 to prevent 
formation of the trans-syn form, whereas the presence of the methylene linking group 
between the carbohydrate and imidazolyl units in 20a and 20b allows the bulky carbohydrate 
to adopt positions that permit the formation of both the trans-syn and trans-anti forms. 
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Examination of the PdBr2(NHC)2 analogues of 10, the PdCl2(NHC)2 analogues of 20a-20c, 
and variable temperature NMR studies, would shed light on this interesting subject.  
 
A more recent study suggests that the isomerism seen by Lin and coworkers was indeed a 
consequence of the bulk of the ancillary ligands (i.e., the PdBr2 core) in 20a-c. Nishioka and 
coworkers reported Ni(II) complexes 40 and 41 that were analogues of the Pd(II) complex 10 
studied by Glorius’ group. Unlike 10, both 40 and 41 showed two sets of NMR signals in 
solution, a result consistent with the presence of trans-syn and trans-anti isomers, and the 
presence of the bulky NiBr2 core prevents rapid rotation of the NHC units about the Ni-C 
bonds, so that these two forms remain distinct on the NMR timescale. In an X-ray diffraction 
study, 40 was found to exist in the trans-syn conformation, while 41 adopted the trans-anti 
conformation [84]. It was suggested that in the latter case, interactions between axial 
hydrogens of the glucopyranosyl substituent of one NHC and the pi-system of the benzyl 
substituent of the other NHC unit may have contributed to the preference for the trans-anti 
conformation. 
 
Scheme 19. 
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Nishioka and coworkers reported variable temperature NMR studies of Ni(II) complexes 40 
and 41 (Scheme 19). The NMR spectra showed complicated temperature dependencies, 
which were interpreted in terms of (i) a change in the relative amounts of syn and anti forms 
with temperature and (ii) occurrence of more than one exchange process. They suggested that 
in addition to the substantial rotation of NHC ligands about the Ni-C axis that results in syn / 
anti exchange, for the syn form, a smaller twisting motion would result in interconversion of 
diastereomers syn-Ra and syn-Sa (Fig. 4) that differ due to axial chirality about the C-Ni-C 
axis, the effects of the latter only becoming manifest at lower temperatures. Additional 
processes, such as rotation of the carbohydrate moiety about the carbohydrate-N bond, might 
also have an effect on the NMR spectra.    
 
Fig. 4. Equilibrium proposed to account for the temperature-dependence of NMR spectra of 
40 and 41.  
 
Nishioka’s group also demonstrated the first example of a diastereoselective synthesis of an 
NHC complex induced by anomeric isomerism of a carbohydrate unit in a ligand. They 
synthesized the imidazolium salts 42 (Scheme 20) containing a tetraacetylglucopyranosyl 
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moiety in either the α- or β-D-anomeric forms (S and R configurations respectively), and used 
this imidazolium salt as a precursor to Rh(III) and Ir(III) complexes 43 and 44 (Scheme 
20) [85]. In these complexes the metal centre is pseudo-tetrahedral and therefore a 
stereocentre that can be assigned an R or S configuration. The carbohydrate moiety induced 
chirality at the metal centre — for imidazolium salts containing the carbohydrate moiety in 
the α-D-anomer (anomeric carbon of S configuration) the dominant configuration of the 
metal centre in the resulting complex was S, and for imidazolium salts containing the 
carbohydrate moiety in the β-D-anomer (anomeric carbon of R configuration) the dominant 
configuration of the metal centre in the resulting complex was R. In each experiment, the 
major diastereomer was isolated and the configuration of the metal centre was confirmed by 
X-ray diffraction studies. 
 
In compound 23 (Scheme 11), the chelating (NHC)2(triazole) ligand is not planar, but forms 
a helical arrangement around the Pd centre. The chelating ligand can adopt M- or P-helicity, 
and the presence of the chiral D-tetraacetylglucosyl moiety causes the two forms to be 
diastereoisomers (Scheme 21) [50]. These two diasterisomers exist in a 1:1.3 ratio in solution 
and give rise to distinct sets of signals in the 1H NMR spectrum at room temperature [50]. At 
150 °C, the signals merge into a single set of sharp signals, indicating that the M- and P-
isomers interconvert rapidly on the NMR timescale at elevated temperatures.  
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Scheme 20. 
 
 
Scheme 21. 
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Shi et al. synthesized an imidazolinium salt 45 containing carbohydrate moieties attached to 
both nitrogen atoms and converted this precursor into a Rh complex 46 (Scheme 22) [86]. 
The NMR spectra of 45 indicated that the imidazolinium salt had C2 symmetry, which 
indicates that the two carbohydrate moieties had the same stereochemical configuration (a C2 
axis co-linear with the imidazolinium C2-H bond renders the two carbohydrate environments 
equivalent). In 46, coordination of the NHC to the Rh(Cl)(COD) unit breaks the C2 symmetry, 
but the two carbohydrate environments would be equivalent on the NMR timescale if the 
NHC ligand were to undergo rapid rotation about the Rh-C axis. The observation that the 
carbohydrate environments in 46 are not equivalent and NMR spectra are more complex 
suggests that rotation about the Rh-C axis is slow on the NMR timescale. 
 
 
 
 
Scheme 22. 
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6. Summary and Outlook 
 
Combining NHCs and carbohydrates together as ligands in metal complexes is a challenging 
yet potentially rewarding endeavour in organometallic chemistry.  
 
In catalysis research, a carbohydrate moiety in the catalyst can provide a chiral motif and 
potential water solubility. Thus, it might be a cheap and simple way of achieving both 
asymmetric catalysis and catalysis in an aqueous medium. Preliminary results obtained for 
some carbohydrate-NHC complexes as catalysts for reactions in aqueous media are 
promising, with high yields being obtained in several cases. On the other hand, existing 
studies of complexes with carbohydrate-NHCs showed little utility in asymmetric catalysis. 
Their enantioselectivity was relatively poor compared with existing chiral catalysts, 
presumably due to the carbohydrate motif being too far from the metal centre. Better 
enantioselectivity might be achieved by catalysts incorporating more complex carbohydrate 
moieties, or designed so that the carbohydrate moieties are directed more towards the metal 
centre; investigation of asymmetric catalysis by complexes such as 46 would be interesting in 
this regard.  
 
In medicinal chemistry, the introduction of a carbohydrate moiety into NHC complexes 
opens up the possibility for modulation of solubility and lipophilicity, and targeted delivery 
of compounds to particular cells (by commandeering, for example, glucose transporters). For 
such applications, to prevent displacement of the carbohydrate moiety from the metal by 
other ligands (albumin, cysteine etc.) in the biological milieu, the carbohydrate moiety should 
be an appendage to the strongly-bound NHC ligand, rather than bound to the metal directly as 
(for example) a thiolate ligand. With appropriate molecular design, this approach can also 
provide longer distances between the carbohydrate group and metal centre and its ancillary 
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ligands, which may be important for carbohydrate presentation for recognition by 
transporters or other types of biological activity. The ease of modification of NHCs/azolium 
salts via well-established procedures allows for further tuning of lipophilicity and reactivity 
of the NHC-carbohydrate metal complex if need be. Results obtained from studies of the 
biological activity of carbohydrate-NHC metal complexes that have been reported to date 
have been mixed. At this stage, it is too early for firm conclusions to be drawn about the best 
ways to incorporate carbohydrates or their derivatives into NHC metal complexes for 
optimum catalyst design or to modulate specific biological targets of therapeutic interest. 
Given the vast number of possible carbohydrate and carbohydrate-derived structures and the 
number of potential applications, further work is required to unlock the full potential of this 
exciting new field. 
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Highlights 
• It is relatively easy to synthesize NHC ligand with carbohydrate moieties attached. 
• Carbohydrate groups impart water solubility to NHC metal complexes 
• The complexes can serve as water soluble and/or asymmetric catalysts 
• NHC analogs of Auranofin exhibit promising anti-cancer properties in vitro. 
 
